Shows
Life Sciences WeeklyJune 28, 2025 - Life Sciences Weekly RecapLife Sciences Weekly - Episode 7Recorded: June 28, 2025In Episode 7 of Life Sciences Weekly, host Matt Davison delivers a comprehensive roundup of the week’s biggest developments in biotech, pharma, and medtech as of June 28, 2025. Tune in for a detailed market snapshot—including ETF performance and sector drivers—before diving into a packed slate of FDA approvals and regulatory actions, from Stryker’s new ankle system and the first sutureless nerve repair device to expanded Alzheimer’s imaging labels and major cancer therapy advances. The episode covers key funding rounds, including CalmWave, ForSight R...2025-06-2820 min
The Animalz Content Marketing PodcastAditya Vempaty (MoEngage) on Borrowed Authority: Partnerships That Multiply ReachEnterprise content only works when people see it. In this episode, Aditya Vempaty, VP of Marketing at MoEngage, shows you how to build content that spreads and brings in revenue.He starts every project with customer calls. Their words turn into clear messages and sharp ideas. His team builds content “with distribution in mind,” leverages customer research as a non-negotiable input, and uses “borrowed authority” from partners and customers to widen reach. They delete dead posts, keep the few that pull traffic, and rebuild tight topic clusters that tie straight to revenue.2025-06-2449 min
Condensed IPAgilent v Synthego (Fed. Cir., June 11, 2025) 2023-2186This Federal Circuit opinion concerns an appeal from Agilent Technologies, Inc. against Synthego Corp., concerning the patentability of gene-editing technology related to CRISPR-Cas systems. Agilent appealed decisions by the Patent Trial and Appeal Board, which found all claims of Agilent's U.S. Patent Nos. 10,337,001 and 10,900,034 unpatentable due to anticipation or obviousness based on prior art. The core of the dispute revolves around whether earlier works, particularly "Pioneer Hi-Bred," "Threlfall," and "Deleavey," expressly disclosed or enabled the chemically modified guide RNAs (gRNAs) and their functionality as claimed by Agilent. The court ultimately affirmed the Board's findings, concluding that substantial evidence...2025-06-1518 min
#ThroughTheGenes#ThroughTheGenes – Season 2 TrailerIn Season 2, we go deeper—confronting ethical dilemmas, highlighting critical clinical insights, and sharing unfiltered patient experiences that matter most to the sickle cell community. This season empowers warriors, caregivers, and providers with knowledge to navigate curative therapies with clarity and confidence. We also introduce our newest sickle sister, Christelle Salomon,🧬 Featured Experts & Guests:Dr. Mark WaltersDr. Matthew PorteusDr. Akshay SharmaDr. Elizabeth KriegerChris LundyOladapo (Daps) BakareDr. Marsha TreadwellSupported by Beam Therapeutics, Synthego Corporation®, and Kamau...2025-05-1306 min
cc: Life Science PodcastLife Science Sales - Old Way vs New WayRecently, I’ve enjoyed interviewing people I have never spoken to before. Harrison Waid, the co-founder of Succession, is one of those. Shout out to Teddy Lin for connecting us. I took this as an opportunity to learn about Harrison and his business as well as a personal challenge to interview someone “cold”. OK, I did some research, so maybe “room temperature”.First of course, I needed him to explain Succession, co-founded with Nick Clare (who I hope to have on another time). They noticed life science companies struggling to translate great technology into successful market entry and sales...2025-05-0730 minLife Science Marketing RadioLife Science Sales - Old Way vs New WayRecently, I’ve enjoyed interviewing people I have never spoken to before. Harrison Waid, the co-founder of Succession, is one of those. Shout out to Teddy Lin for connecting us. I took this as an opportunity to learn about Harrison and his business as well as a personal challenge to interview someone “cold”. OK, I did some research, so maybe “room temperature”.First of course, I needed him to explain Succession, co-founded with Nick Clare (who I hope to have on another time). They noticed life science companies struggling to translate great technology into successful market entry and sales...2025-05-0730 min
The Exit Five CMO Podcast (Hosted by Dave Gerhardt)The 7 Marketing Metrics Every B2B Leader Should Report On#235: Strategy |In this episode, Matt sits down with Aditya Vempaty, VP of Marketing at MoEngage, to talk about a topic every marketing leader has wrestled with: reporting on the right metrics. Aditya has led marketing at companies like Nutanix, Amplitude, and Synthego - and he’s learned how to build dashboards and reporting frameworks that actually communicate marketing’s impact across leadership, sales, and finance.Matt and Aditya cover:Why marketing metrics should translate performance into a common language the business understandsThe four buckets of metrics every B2B team should trackHow often you should be repo...2025-04-0745 min
The Capitalism and Freedom in the Twenty-First Century PodcastProductivity, Innovation, and the New American Golden Age with Joe LonsdaleJon Hartley and Joe Lonsdale discuss Joe’s career, co-founding Palantir, Addepar, and OpenGov, venture capital investing, defense tech, DOGE, Elon Musk, regulation, and the prospects for generative artificial intelligence.
Recorded on December 12, 2024.
ABOUT THE SPEAKERS:
Joe Lonsdale is the founder and managing Partner at 8VC, an early-stage venture capital firm managing over $6 billion in capital. In 2003, he founded Palantir Technologies (NYSE:PLTR), a global software company known for its work supporting US and its allies’ defense and intelligence. Since then, he has founded more than a dozen prominent companies, including Addepar, a weal...2025-02-061h 04The Capitalism and Freedom in the Twenty-First Century PodcastProductivity, Innovation, and the New American Golden Age with Joe LonsdaleJon Hartley and Joe Lonsdale discuss Joe’s career, co-founding Palantir, Addepar, and OpenGov, venture capital investing, defense tech, DOGE, Elon Musk, regulation, and the prospects for generative artificial intelligence.
Recorded on December 12, 2024.
ABOUT THE SPEAKERS:
Joe Lonsdale is the founder and managing Partner at 8VC, an early-stage venture capital firm managing over $6 billion in capital. In 2003, he founded Palantir Technologies (NYSE:PLTR), a global software company known for its work supporting US and its allies’ defense and intelligence. Since then, he has founded more than a dozen prominent companies, including Addepar, a weal...2025-02-061h 04
Biotech BeatArtemisa - CCSF Alum - Senior Lab AssociateIn this episode of the Biotech Beat Podcast, Artemisa shares her journey from studying marine biology in Mexico City to becoming a senior lab associate at Synthego in San Francisco, CA. Artemisa discusses her passion for biotechnology, particularly CRISPR technology, and the supportive work environment at Synthego. Artemisa emphasizes the importance of education, skills, and networking for success in the biotech industry. She highlights the unique company culture at Synthego that fosters collaboration and growth. Artemisa offers valuable advice for aspiring biotech professionals, highlighting the significance of professionalism and reaching out for help.
Takeaways:
Artemisa...2025-02-0322 min
Invested by AlephPalantir Co-Founder Joe Lonsdale on Fixing America, Disrupting Defense Innovation & Building the University of AustinOn this episode of Invested, Michael hosts Joe Lonsdale, a venture capitalist, serial founder and philanthropist. Joe Lonsdale is the Founder and Managing Partner at 8VC, an early-stage venture capital firm managing over $6 billion in capital. In 2003, he founded Palantir Technologies (NYSE:PLTR), a global software company known for its work supporting US and its allies’ defense and intelligence. Since then, he has founded more than a dozen prominent companies, including Addepar, a wealth management platform with about $5 trillion, and OpenGov, the leading cloud software provider for local governments. He continues to create and sc...2024-10-281h 07
LEVITYEpisode #7 - Mark HamalainenThere are countless reasons to admire Mark Hamalainen, and one of them is his brutal honesty. While many longevity influencers confidently declare that longevity escape velocity and indefinite lifespans are just around the corner, you won’t get such easy assurances from Mark.That’s because, and this might seem counterintuitive at first, he’s one of the most deeply committed advocates for solving aging that I’ve encountered. Mark, a former director of science at Synthego and a former researcher at SENS Research Foundation (Aubrey de Grey has called him his protégé), has dedicated over two decade...2024-09-031h 51
Ed on the EdgeEp 20 · Joe Lonsdale | Founder & Managing Partner of 8VCwww.dashmedia.coEntrepreneurs. Educators. Investors. Policymakers. Hosted by GSV Founder & CEO Michael Moe, Ed on the Edge covers the "who" and the "how" of driving change in the global education landscape.Joe Lonsdale is the Founder and Managing Partner at 8VC, an early-stage venture capital firm managing over $6 billion in capital. In 2003, he founded Palantir Technologies (NYSE:PLTR), a global software company known for its work supporting US and its allies’ defense and intelligence. Since then, he has founded more than a dozen prominent companies, including Addepar, a wealth management platform with about $5 tri...2024-08-2132 min
Anatomy Of IllnessEpisode 15: Sickle Cell Anaemia - Not the Regular Anti-MalarialSickle cell anaemia: What is it? What are its symptoms and genetics? In this episode, we will explore the history, treatment, and the reasons behind the existence of this condition. The episode will also explain the potential complications associated with sickle cell anaemia. Tune in to find out more.
Check out our website: https://anatomyofillness.com/
Thehemenp: https://www.instagram.com/thehemenp?igsh=MW4zMXB4engxb3NzdQ==
Books about Sickle Cell Anaemia: https://scinfo.org/patients-families/books-for-patients-and-families/
Sickle Cell Disease Foundation: https://www.scdfc.org/
Sickle...2024-05-3017 min
CRISPR CutsImran House and Junyun Lai Discuss CRISPR Screening in Immuno-OncologyImran House, Ph.D. and Junyun Lai Ph.D. are Senior Scientists at the biotech start-up, ONKo-Innate in Melbourne, Australia that focuses on developing immuno-oncology therapies. In this episode they discussed what they do at oNKo-innate, their career transitions from leaving academics to entering the biotech industry, and how CRISPR is impacting cancer-immunotherapy development. They also discussed overcoming common obstacles faced when developing cytokine therapies and future outlooks on clinical trials using these kinds of therapies.
Reach out and connect with both Imran and Junyun on social media platforms:
Imran House, Ph.D.2024-01-3126 min
SalesDNA: Decoding life science sales[Leadership] Growing multiple startups and the sh*t umbrella with Ted TischTop takeaways: - He shares his ACB framework- How you need to think about brand- Effective ways to up-level your sales team- How goals get passed down from the board to your quotaWatch this episode on Youtubehttps://www.youtube.com/playlist?list=PLNpnig-8yQuwbM5AueF_cDRub_GQW5FB2About: - Ted Tisch- https://www.linkedin.com/in/theodoretisch/- GM at BioRad and COO at Synthego and MammothDownload the life science sales rep toolkit: https://www.succession.bio/content/life-science-sales-toolkit...2024-01-1636 min
#ExpertAnswers - an InsideScientific Podcast#ExpertAnswers: Travis Hardcastle and Seth Hanson on Using CRISPR and iPSCs for Neuroscience ResearchTravis Hardcastle from Synthego and Seth Hanson from BrainXell answer questions from a webinar where they discuss innovative applications of CRISPR and iPSCs in disease modeling and drug discovery.
2024-01-0606 min
Foresight Institute RadioMark Hamalainen | A Coherent, Executable Plan to Achieve Unlimited Healthy LifespanMark Hamalainen is cofounder of the Longevity Biotech Fellowship. His career has progressed from manual bench work in academia, to lab automation at Synthego, to longevity movement building - always seeking better methods and higher leverage ways to accelerate progress.He shares an actionable roadmap for an unlimited healthy lifespan, divided into four promising areas for progress. He shares updates and information regarding The Longevity Biotech Fellowship, whose mission is to enable a future where everyone can access a healthy, unlimited lifespan. Dive deeper into the session: Full Summary2024-01-0551 min
Right Up Your AlgaeCRISPR? I hardly know her: A look at the controversial gene editing techniqueClara tells Emily what the heck Clustered Regularly Interspaced Short Palindromic Repeats are, goes into some of the uses of the gene editing technique, and discusses some of the controversy surrounding CRISPR worldwide.Sources:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342697/https://www.synthego.com/blog/gene-editing-nobel-prize#charpentier-and-doudna-win-nobel-prize-in-chemistry-for-developing-crispr-technologyhttps://www.jax.org/personalized-medicine/precision-medicine-and-you/what-is-crisprhttps://medlineplus.gov/genetics/understanding/genomicresearch/genomeediting/https://www.synthego.com/blog/crispr-applicationshttps://www.science.org/doi/10.1126/science.1258096https://www.genome.gov/about-genomics/fact-sheets/Eugenics-and-Scientific-Racism#:~...2023-11-1524 min
Life, Science and MarketingHarrison Waid and Nick Clare: Key takeaways from a special edition episode focused on debating life science marketing vs salesLife, Science, and Marketing Podcast: Episode 7Guests: Harrison Waid and Nick ClareHarrison's Background:Co-founder of SuccessionPreviously in software sales at Synthego before pivoting to biotechNick's Background:Co-founder of SuccessionExtensive experience in life sciences and drug discovery having worked with pharma companiesCurrently Interim CBO at DefinigenKey Discussion Points:Perception gap between marketing and sales teamsConfusion over lead qualification terminologyMarketing content often lacks value for sales teamsImportance of not distracting sales with customer issuesStrategies for marketing to gain credibility in sales-driven organisationsBenefits of RevOps function to align goalsAdopting a...2023-11-0855 minCRISPR CutsMark DeWitt and Don Kohn Discuss Their ex vivo CRISPR-based Therapy to Cure Sickle Cell AnemiaDr. Mark DeWitt Ph.D., Associate Director at Mammoth Biosciences, and Dr. Don Kohn M.D., distinguished professor and Director of the UCLA Human Gene and Cell Therapy Program and CIRM grantee sat down with us to discuss their latest clinical trials to cure sickle cell anemia, how synthetic guides accelerated their journey from the bench to the clinic, and their experience in the cell and gene therapy space.
2023-10-2033 minCRISPR CutsDina Simkin Breaks Down Epilepsy Cell ModelingDina Simkin, Professor of Neurology at Northwestern University, joins us in this episode of CRISPR Cuts. Dr. Simkin talks about her path to becoming a researcher, art, and the importance of patient and isogenic iPSC models to study genetically linked forms of epilepsies.
2023-05-1627 minCRISPR CutsSunil Sharma and Raffaella Soldi Talk CRISPR For Unbiased Drug Screening for Rare Pediatric CancersDr. Sunil Sharma and Dr. Raffaella Soldi of the Translational Genomics Research Institute chat about using CRISPR arrayed screens to identify novel drug targets for Ewing's Sarcoma, outlooks for the future of cancer therapies, and the Arizona heat.
2023-04-2524 minCRISPR CutsStephanie Cherqui Discusses Clinical Development of CRISPR Therapies for Rare DiseasesProfessor Stephanie Cherqui, UCSD, has worked on the development of cell therapies for two rare genetic diseases, cystinosis and Friedreich’s ataxia. In this interview, Dr. Cherqui chats about her experience working on rare diseases, developing a CRISPR-edited therapy for Friedreich's ataxia, navigating regulatory challenges in cell and gene therapies, and more.
2023-03-2020 min
Speaking of Mol BioCRISPR | Making the world betterSince it’s discovery, CRISPR Cas9 gene editing technology has blossomed and boomed. It’s moved from a highly technical niche technique to one that is arguably mainstream and being applied to countless challenges in applied biology. In this episode we talk with Travis Hardcastle, who previously worked in R&D to develop gene editing products and is now a Product Manager for Engineered Cell Lines at Synthego. Travis helps explain the basics of gene editing and how it’s being applied to cell line engineering and provides a well-informed perspective on the past, present, and future of the CRISPR...2023-01-2729 minCRISPR CutsChristian Groendahl On Pioneering a CRISPR-based Microbial Gene TherapyTune in to hear Christian Groendahl, CEO of SNIPR Biome, talk about CRISPR editing in prokaryotes, their novel E. coli-targeting CRISPR therapy trials, and his experiences and vision leading a start up.
2022-12-0529 minCRISPR CutsBryan Dechairo Envisions an Accessible Future for CRISPR DiagnosticsIn this episode, Bryan Dechairo, CEO of Sherlock Biosciences, talks about the impact of technology advances in the field of CRISPR diagnostics, his experiences leading Sherlock Biosciences, and his team’s mission of accessibility.
2022-09-0635 min
Nice Genes!Nodding our Tusks to Heroic MutationsJust like any good superhero comic, we start this episode with the science going incredibly wrong. Think: vats of toxic waste producing evil mutants that ravage the city. Or maybe not so evil. It really depends on your perspective. Just like the X-men, genetic mutations get a bad rap in the public eye. But they aren’t all nasty.Dr. Kaylee Byers speaks with data scientist and evolutionary biologist Dr. Brian Arnold on how the genetic ‘mistakes’ known as variants occasionally encode incredible abilities. Odd elephants, immortality hiding in our ocean depths, and Rogue-ish bacteria are just a few...2022-08-0200 minCRISPR CutsAyal Hendel Talks About CRISPR in Bubble Boy DiseaseDr. Ayal Hendel, a genome-editing pioneer and group leader at Bar Ilan University in Israel, was one of the first researchers to use modified synthetic sgRNA to edit primary cells with CRISPR. In this episode, Dr. Hendel shares his perspectives on the recent CRISPR advancements and his work on the bubble boy disease.
2022-06-0735 minCRISPR CutsJimi Olaghere Opens up About His Sickle Cell Disease and CRISPR TrialJimi has dealt with sickle cell disease, a genetic disorder with serious implications, his entire life. Undergoing a CRISPR gene editing trial turned his hope for a cure into reality with promising results from the early phases. Tune in to learn about Jimi's journey in this episode.
2022-05-0539 minCRISPR CutsTJ Cradick Speaks About Their HIV CRISPR Therapy in TrialsTJ Cradick, Chief Scientific Officer at Excision Bio, discusses their CRISPR HIV therapy that recently proceeded into clinical trials in this episode and their ongoing work on other viral diseases.
2022-03-3123 minCRISPR CutsBryce Olson Relays His Experience on Personalized Therapies for Cancer PatientsAfter being diagnosed with aggressive prostate cancer, Bryce Olson quickly learned the science behind it and has leveraged NGS to understand his tumor genomics and find opportunities in personalized therapies. Hear the patient perspective for the first time on our podcast through Bryce's narration of his experience and pursuit of next generation cell and gene therapies.
2022-03-1542 minCRISPR CutsNeville Sanjana Discusses Ways to Enhance CRISPR-Cas13 Knockdown in Human CellsIn this collaboration episode with NEB, we interview Dr. Neville Sanjana, a core faculty member at the New York Genome Center, about his recent publication in which chemically modified guide RNAs were used to enhance CRISPR-Cas13 knockdown in human cells.
2022-01-2832 minCRISPR CutsKiana Aran Chats About her Nature Award and New Non-ProfitIn this episode, we chat with Dr. Kiana Aran, the CSO of Cardea Bio and associate professor at Keck Graduate Institute, who recently won the Nature Research Award for Inspiring Women in Science. Dr. Aran talks about her experience being a nominee and award winner, her early days and scientific journey, and the launch of her new non-profit, Aran Nebula.
2021-11-1541 minCRISPR Cuts6 Women CRISPR Leaders Get Candid About Their Journeys to the TopWe chatted with six female leaders in the CRISPR—Alison van Eenennaam, Ph.D., Kiana Aran, Christina Trojel-Hansen, Ph.D., Laura Lambert, Ph.D., Elena Miñones Moyano, Ph.D., and Samantha Maragh, Ph.D.— about their professional journeys.
Tune in to this episode for a candid and honest discussion on a broad range of topics, including their experiences as women of color, life as working moms, adjusting in male-dominated fields, experiences being part of the LGBTQIA community, and the role of mentors in professional development.
2021-10-281h 02CRISPR CutsJesse Boehm Discusses Tackling Rare Cancers Using CRISPRIn this CRISPR Cuts episode, Dr. Jesse Boehm, the Chief Scientific Officer of the Break Through Cancer Foundation and principal investigator at the Broad Institute, talks about his work on rare cancers. He also covers how CRISPR technology is transforming cancer research.
2021-07-2830 minCRISPR CutsNIH Scientists Discuss the iNDI Project for Alzheimer's Disease ModelingThe Inducible Pluripotent Stem Cell Neurodegeneration Initiative (iNDI), an NIH effort, aims to standardize disease models for Alzheimer’s and related dementias. Hear the principal contributors, Dr. Michael E. Ward and Dr. Mark R. Cookson, scientists at the NIH, talk about the inception of the iNDI project, the challenges and opportunities, and the future of neurodegenerative research.
2021-06-1437 minCRISPR CutsJoe Miano Talks About Prime Editing in MicePrime editing is a new genome engineering tool that emerged just a couple of years back. Right from the get-go, this technology made waves as a potential alternative to CRISPR. Now, the first comparative study in mice is out. Dr. Joe Miano, Professor at the Augusta University in Georgia, talks about their collaborative work comparing traditional CRISPR-mediated homology-directed repair with prime editing in mice.
2021-05-2619 min
The Weirding Hour24 - GeneticsThis week's episode looks into genetics while we make stuff out of... tape? See us try make that relevant on our socials!
See what we crafted: Instagram/Twitter @weirdinghour, Facebook @theweirdinghour
Craft along with us: #weirdinghour if you want to share what you made!
To suggest crafts or topics: email weirdinghour@gmail.com
Spread the weird~
[This episode was recorded via Skype due to lockdown]
Sources:
Bothwell:
https://en.wikipedia.org/wiki/X-Men
2021-05-201h 18
The Sean Lowery ShowThe Sean Lowery Show - Ep 97 - Kevin Holden - What is CRISPR?The Sean Lowery Show - Ep 97 - Kevin Holden
CRISPR
I am so fascinated by this topic, and I've been looking for someone to discuss this with. I mostly talk about entrepreneurship & business. I'm no scientist, and I've listened to a good amount of podcasts on this subject.
It was hard to find someone for this topic but luckily we found the perfect person!
Kevin Holden, Ph.D., Microbiology
Kevin Holden is head of Science at Synthego
https://www.synthego.com
He was in the Netflix Movie: Human Nature
https://www.netflix.com/title/81220944
ABOUT SYNTHEGO
Synthego’s Genome Engineering Pl...2021-05-1958 min
Phosphatidylserine, Cortisol & Testosterone Dr. Cam | Maximus Live #47Actionable Advice From The Billionaire Joe Lonsdale | Career Success, Leadership & MasculinityIn this episode, Joe Lonsdale gives actionable advice on multiple topics such as how to organize your day, what to focus on when thinking about career success and how to stay motivated. Joe founded Palantir, a $44B public company, and was an early institutional investor in notable companies including Wish, Oculus, Oscar Health, Synthego & Guardant Health. In 2017 he was the youngest member of the Forbes 100 Midas List. He studied at Stanford and has a BS in Computer Science. He is the founder of 8VC a venture capital firm that invested in us and where I’m an advisor as we...2021-05-1845 min
BIOS13. Bio-Industrial Age: Francisco Gimenez & David Moskowitz - 8VC Bio Team8VC is a Silicon-Valley based technology investment firm investing in visionary teams and backing industry-transforming companies, currently managing $3.5bn in AUM. About one third of their current fund is dedicated towards the BioIT space. 8VC’s portfolio represents a large early crop of now next gen biotech unicorns including but not limited to Orca Bio, Synthego, Resilience, and Lyell Immunopharma which have generated playbooks for others startups to follow.Francisco Giminez and David Moskowitz are two integral members of the 8VC team which developed the Bio-IT investment thesis. Francisco is a Partner @ 8VC focusing on Bio...2021-05-141h 17Phosphatidylserine, Cortisol & Testosterone Dr. Cam | Maximus Live #47Making The Man Joe Lonsdale The Multimillionaire, Entrepreneur & InvestorIn This Episode, Dr. Cam interviews the millionaire entrepreneur and investor Joe Lonsdale. Joe founded Palantir, a $44B public company, and was an early institutional investor in notable companies including Wish, Oculus, Oscar Health, Synthego & Guardant Health. In 2017 he was the youngest member of the Forbes 100 Midas List. He studied at Stanford and has a BS in Computer Science. He is the founder of 8VC a venture capital firm that invested in us and where I’m an advisor as well. Altogether, these funds manage over $3.5 billion in capital.2021-05-1040 minCRISPR CutsIGI Researchers Are Using CRISPR to Reduce Cyanide in CassavaDid you know cassava can cause cyanide poisoning if it is not processed correctly and consumed with a protein-poor diet? In this episode, we chat with IGI researchers, Jess Lyons and Michael Gomez about their work on using CRISPR to reduce cyanide in cassava and improve its food safety.
2021-04-2826 min
SALT TalksVenture Capital & Early Stage Science Startups | SALT Talks #156Joe Lonsdalewas an early institutional investor in notable companies including Wish, Oculus, Oscar, Illumio, Blend, Orca Bio, RelateIQ, Joby Aviation, Synthego, Guardant Health, and in 2016 and 2017 was the youngest member of the Forbes 100 Midas List. He is also the co-founder of Palantir, a multi-billion dollar global software company best known for its work in defense and finance. Most recently, he was a founding partner at Formation 8, one of the top-performing private funds and the precursor to 8VC.Dakin Sloss is an entrepreneur, investor, and philanthropist. He is the Founder and General Partner of Prime Movers Lab, the w...2021-03-3147 minCRISPR CutsKevin Davies Chats About His Latest Book "Editing Humanity"Kevin Davies, the executive editor of The CRISPR Journal, has closely watched the genetics space evolve over the last decades. His expertise and experience were the perfect foundation for his latest book "Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing." In this episode, Kevin discusses his motivation for the book, along with some behind-the-scenes stories when writing this timely literature piece.
2021-03-3032 minCRISPR CutsMichael Friend Advocates For Diversity in CRISPRIn this episode, Michael Friend, CEO of Minority Coalition for Precision Medicine, discusses the lack of diversity in genome editing field and covers potential solutions for ensuring an inclusive future, particularly for black scientists.
2021-02-2418 minCRISPR CutsCRISPR Forecast 2021 with Paul Dabrowski and Robert DeansIn this episode, Paul Dabrowski, CEO of Synthego, and Robert Deans, CSO of Synthego, discuss the CRISPR silver linings of 2020 and predict the directions and milestones for gene editing in 2021.
2021-01-1217 min
When Science SpeaksStart-ups and Storytelling with Nathaniel Brooks HorwitzNathaniel Brooks Horwitz has had a set of rare experiences - particularly for someone still in the early stages of his career journey. His passion is to develop new medicines. A Principal at RA Capital, a leading biotech venture capital firm in Boston, board member at Synthego Corporation, Quench Bio, GentiBio and others, Nathaniel was previously founding CEO of Nivien Therapeutics. On today's episode, Mark and Nathaniel discuss a range of topics, including: - How Nathaniel proceeded from research at Harvard University through founding his own company, dealing with the crosscurrents he described...2021-01-0829 min
Root Of All RandomROAR Ep11 - What if Genetic Engineering was a Black Mirror Episode?Genetic engineering has been making its way into pop culture for decades. Whether it’s glorified or heavily condemned, genetic engineering is just one of those things that will continue to manifest in the modern world. In this episode of ROAR we look into where it all started, where we’re at now and what advancements in this field can mean for our future. Can we come up with the ultimate apex predator (yes Jurassic World I’m talkin’ to you)? What about a chilling Black Mirror episode? Tune in to our final episode of 2020 to find out what we come...2020-12-281h 14
SteministasWhat is the science behind X-Men?The original X-Men movie brought the Marvel comics to life for the first time in 2000. And years before the completion of the human genome project or the discovery of CRISPR, this film already opened up interesting questions about genetics when we reflect back 20 years later! In this episode we discuss the science behind X-Men and the politics and ethics of classifying individuals as mutants versus normal.
SOURCES: //
Genetic changes happening during puberty: https://www.nature.com/articles/ng.3841
Genetics behind X-men:
http://www.wiringthebrain.com/2016/03/the-surprising-real-genetics-behind-x.html
We’re all m...2020-10-0618 min
Demand EfficiencyAditya Vempaty of Synthego on retention as a marketing-driven metric and a focus on customers instead of productPodcast outline[01:35] Aditya’s background[03:20] What consumers care about more than your product[05:35] Why companies need to identify the problems prospective customers are trying to solve[08:45] Why retention is more important than acquisition[10:48] The biggest lesson Aditya has learned in his career[12:00] How Aditya builds trust with consumers through “problem marketing”[13:35] Why building community is important and how Aditya builds community [14:24] What it was like for Aditya to go from a SaaS product to biotechnology[16:31] How Youtube will be leveraged more in a B2...2020-08-1221 min
Salty LanguageChippendev's This week Bryan and Tony discuss their week, Call of Duty update, PS5 reveal, medium's podcast, Louis C.K.'s new special, Dave Chappelle's new special, HOBI, cop abuses power so he can flirt with woman, Tom Morello's angry fan, Galactus HeroClix, our QoftheW, and more! Shirts: https://www.teepublic.com/t-shirt/5643020-salty-language-core-shirt Our Patreon: Patreon.com/saltylanguage Bryan's Go Fund Me: https://www.gofundme.com/9a7ce-life-reset&rcid=r01-15522763109-dfc5d1f679c94a45&pc=tw_co_campmgmt_w Links: 1. Chappelle special https://www.youtube.com/watch?v=3tR6mKcBbT4 2. Crispr https://www.livescience.com/58790-crispr-explained.html 3. Podcasts about Crispr...2020-06-172h 18
Tech QualifiedGenome Engineering and Marketing Tactics with Aditya Vempaty of SynthegoDuring this episode of Tech Qualified, Tristan Pelligrino chats with Aditya Vempaty, the VP of Marketing at Synthego. Aditya chats about his past working experience prior to Synthego and highlights how it’s important to build trust with prospects with B2B marketing. Aditya also covers why he enjoys the startup culture so much and pinpoints what drives him as a marketer. Episode Highlights Aditya’s education included an electrical engineering degree from Georgia Tech and he started his professional career as a programmer before moving into a marketing role. Aditya discusses his inclination towards startup envir...2020-06-0238 minCRISPR CutsCRISPR Office Hours with Hamid GhanadaanThe COVID-19 pandemic is a unique situation for lab scientists, many of whose work has come to a standstill. Hamid Ghanadaan, CEO of Linus, discusses the impact of COVID-19 on science and the next steps for scientists, based on their survey of >1000 scientists.
2020-05-2035 minCRISPR CutsRyan Pawell Talks About Indee Labs’ CRISPR Delivery Technology for Affordable ImmunotherapiesThe mission of Indee Labs, a Berkeley biotech, is to deliver CRISPR reagents into cells using microfluidics for developing affordable cell and gene therapies in the future. We interviewed Ryan Pawell, Founder and CEO of Indee Labs, about the concept of using microfluidics for CRISPR delivery, their mission and ongoing projects, and the convergence of engineering and biology for building scalable platforms.
2020-05-0712 minCRISPR CutsMaking of a CRISPR Film: Behind the Scenes with Producers of Human NatureWhat is the process to make a science film? In this episode, Sarah Goodwin and Elliot Kirschner, producers of Human Nature, a documentary on CRISPR, offer glimpses into making of the film.
2020-04-2337 min
CRISPR CutsLeading St. Jude's Genome Engineering Capabilities: A Chat with Shondra MillerShondra Miller shares her experience of starting a shared genome engineering resource at the St. Jude Children's Research Hospital. Learn more about her research projects and her views on the past, present, and future of the genome editing field in this podcast episode.
2020-01-2810 minCRISPR CutsThe Potential of CRISPR Editing in Stem Cells: An Interview with Bill SkarnesDr. Bill Skarnes, Professor at The Jackson Laboratory, chats about how CRISPR edited stem cells are becoming a gold standard to study gene function and disease modeling.
2019-11-1313 min
The SynBioBeta PodcastHow an artist becomes an investor and advisor to the world’s greatest technology companies - with D.A. WallachToday John Cumbers talks with D.A. Wallach, recording artist and emerging tech investor. John will be talking to D.A. about his journey from performing artist to investor in emerging tech, how his unique background informs his investment thesis, and what opportunities he’s most excited about in synthetic biology these days.
D.A. Wallach is a recording artist, songwriter, and investor. While an undergraduate at Harvard, he was discovered by Kanye West and Pharrell Williams. As a solo artist, D.A. is signed by Harvest Records, a subsidiary of Capitol Records, and he is...2019-09-1152 minCRISPR CutsCRISPR in Fungi: An Interview with Rebecca ShapiroRebecca Shapiro, Assistant Professor at the University of Guelph, talks about CRISPR genome editing in fungal pathogens to understand their disease-causing mechanism. Her lab also works on gene drives in fungi for studying large scale genetic interactions and developing ways for treating fungal biofilms.
2019-09-0418 minCRISPR CutsPaul Dabrowski Gets Candid About the Past, Present, and Future of SynthegoIn this interview, Paul Dabrowski, CEO of Synthego, talks about how Synthego got started, his mantra behind leading the company, and future directions. He also offers insights into Synthego’s unique capabilities—the powerful combination of engineering and biology that enable scaling.
2019-08-0722 min
Talk Nerdy with Cara Santa MariaEpisode 267 - Kevin HoldenIn this episode of Talk Nerdy, Cara is joined by the Head of Science at Synthego, Dr. Kevin Holden. They talk about new advances in genetic engineering technology, such as the CRISPR-CasX system. Also discussed: what the future holds for synthetic biology and related fields. Follow Kevin’s work: @Synthego.2019-07-231h 19
Talk Nerdy with Cara Santa MariaCRISPR w/ Kevin HoldenIn this episode of Talk Nerdy, Cara is joined by the Head of Science at Synthego, Dr. Kevin Holden. They talk about new advances in genetic engineering technology, such as the CRISPR-CasX system. Also discussed: what the future holds for synthetic biology and related fields.2019-07-231h 15CRISPR CutsDana Foss is Solving the CRISPR Delivery Problem to Advance TherapeuticsCRISPR has great potential in therapeutics, but CRISPR delivery in vivo remains a challenge. Researcher Dana Foss discusses her lab’s novel approach for specific delivery of CRISPR components in cells and tissues.
2019-05-2216 minCRISPR CutsSHERLOCK Founders Crack the Case of CRISPR DiagnosticsCRISPR is going beyond gene editing into a new area: diagnostics. Omar Abudayyeh and Jonathan Gootenberg, co-founders of SHERLOCK Biosciences, talk about the present advances and future of CRISPR diagnostics.
2019-05-0921 minCRISPR CutsKiana Aran Chats About Her New Biosensor: CRISPR-ChipKiana Aran, a biomedical engineering expert, talks about her research on CRISPR-Chip, a new biosensor that combines CRISPR & electronics to detect specific genes in genomic DNA.
2019-04-1818 minCRISPR CutsHow the Innovative Genomics Institute is Helping People Understand CRISPRMegan Hochstrasser, Science Communications Manager at the Innovative Genomics Institute, talks about the importance of CRISPR science communication and the ongoing efforts at IGI to help people understand this genome engineering tool.
2019-03-1923 minCRISPR CutsImproving Targeted Delivery to Enhance Personalized MedicineAndre Watson, CEO of Ligandal, talks about how his company is improving the payload delivery of gene therapy, making it more accurate and efficient, to make new gene therapy a reality for the public.
2019-02-2627 minCRISPR CutsAlex Philippidis Reviews Trends in Biopharma & Biotech MarketBiotech and biopharma companies are in a phase of accelerated growth. Alex Philippidis, a science journalist at Genetic Engineering & Biotechnology News discusses the changing face of big pharma, biotech, and CRISPR gene editing industries, as they raise more money and the world changes around them.
2019-02-0727 min
GuidePost, A Podcast Series from The CRISPR JournalEp. 6: Kevin Holden, genome engineerIn episode #6 of GuidePost, Kevin Holden, Head of Synthetic Biology at Synthego Corporation, discusses the company’s Silicon Valley culture, growth, and its approach to providing new gene editing products for the CRISPR community.2019-02-0119 min
Anatomy of NextPaul Dabrowski // Biological FactoryWhat if you could plant a seed, and grow a building? A few episodes ago we talked to Paul Dabrowski, CEO of Synthego, a company building tools that help biologists. Paul's hope for the field of synthetic biology is a path to curing all disease. But in a world of further biological understanding, there are few limits to what we can grow. Let’s talk about the biological factory.2019-01-3009 minCRISPR CutsAvery Posey Discusses CAR T Cell Cancer TherapiesDr. Avery Posey is leading the charge on CAR T cell therapy research to bring this technology to cancer patients as soon as possible. Learn how CAR T works, what stage it’s in now, and how it will help revolutionize the treatment of cancer.
2019-01-2425 minCRISPR CutsTrevor Martin Discusses How CRISPR is Changing DiagnosticsTrevor Martin, CEO of Mammoth Biosciences, talks about the science behind CRISPR diagnostics, and what Mammoth is doing to bring it to consumers in the next decade.
2019-01-1026 minCRISPR CutsCRISPR for Curious MindsIn this Holiday-special mash-up episode, CRISPR Cuts teams up with Curiosity podcast to discuss the ins and outs of CRISPR. Gear up, it's going to be a fun ride!
2018-12-1441 minCRISPR CutsAndrew Porterfield Discusses CRISPR in the Grocery StoreAndrew Porterfield is a scientific marketing consultant, science journalist, and all around science communicator. We caught up with Andrew to discuss the latest news about how CRISPR is impacting the agriculture industry and how the various regulatory decisions related to this technology may shape its use and adoption in different parts of the world.
2018-11-2234 minCRISPR CutsAlison Van Eenennaam Edits Cattle Using CRISPRAlison Van Eenennaam is a geneticist at UC Davis, primarily interested in using CRISPR and other DNA-based biotechnologies in cattle production and agricultural systems. Learn about her exciting projects, ranging from "All Boys" cattle to hornless dairy cows, and the technical difficulties of working with large mammals in this episode.
2018-11-1025 min
Global Venturing Review29 October 2018 – Bytedance Raises $3bn at $75bn ValuationDeals
Bytedance has agreed to raise $3bn in funding from investors including SoftBank at a $75bn valuation that will make it the most valuable independent VC-backed company in the world.
Manbang, the trucking services marketplace also known as Full Truck Alliance, is reportedly in advanced discussions with Tencent and SoftBank over a $1bn round that would value the Chinese company at $9bn.
Huashenghaoche is one of several automotive marketplace operators competing in China’s used vehicle industry, and has secured $210m in a series D round that included JD Finance, the financial services af...2018-10-291h 10CRISPR CutsCRISPR in Gene Drives: Experts OpineGene drives have frequently been in the news in the past few years. In this episode, we discuss what exactly gene drives are, their applications, and how scientists are ensuring that they are used responsibly. Tune in to hear what researchers Anna Buchman from UCSD and Kevin Esvelt from MIT had to say.
2018-10-2310 minCRISPR CutsKnockout Cell Pools Are Simplifying CRISPR ExperimentsDr. Ania Wronski, Product Manager for the Engineered Cells portfolio at Synthego, discusses how their new engineered cells products are enabling CRISPR access to researchers worldwide. Learn about the different ways in which researchers use knockout cell pools & their advantages over RNAi.
2018-10-0420 minCRISPR CutsCRISPR Edited Animals & Their ApplicationsWhat do you think of when you hear the term "transgenic animal"? The hippogriff from Harry Potter? A mouse model to study diabetes? Kevin and Minu discuss what transgenic animals are, how they are used in research, and how CRISPR has changed the transgenic game. After listening, head over to The Bench blog to read more about CRISPR and transgenic animals.
2018-09-1810 minCRISPR CutsCarl Zimmer Discusses Heredity, Genomics, and CRISPRIt's not every day you get to meet one of your idols! Minu and Kevin caught up with Carl Zimmer, an award-winning New York Times columnist and science journalist. Minu chatted with Zimmer and got a rare behind-the-scenes glimpse into his latest book "She Has Her Mother's Laugh" and discussed his views on CRISPR and genomics.
2018-09-0511 minCRISPR CutsReed Kelso Strives to Enable CRISPR Access For All ScientistsReed Kelso, Head of Cell Engineering Research and Applications at Synthego, is a bio-wizard. In this episode, Kevin & Minu catch up with Reed about his role at Synthego and the day-to-day operations at the fast paced start-up. Reed talks about the revolutionary engineered cells products that he and his team recently launched & the hard work behind this amazing achievement. He also speculates about the future applications of CRISPR; his bets are on CRISPR making a massive splash in agriculture!
2018-08-2415 min
GuidePost, A Podcast Series from The CRISPR JournalEp. 3: Rodolphe Barrangou, the CRISPR crazeThe CRISPR Journal Executive Editor Kevin Davis interviews Editor-In-Chief Rodolphe Barrangou. This episode of GUIDEpost is brought to you by Synthego, who's vision is to turn biology into an information science with the ultimate goal of dramatically extending the healthy human lifespan by providing genome engineering solutions. Learn more at www.synthego.com.2018-02-0336 min
Flux07: Paul Dabrowski — The CRISPR RevolutionPaul Dabrowski is co-founder and CEO of Synthego, a company building a platform of tools for scientists. Paul discusses why CRISPR is much more precise than other gene editing techniques, how China has been pushing ethical boundaries, what it's like building a company with your brother, and how his time at SpaceX shaped the way he thinks.2017-02-2700 min